Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Gothenburg – page 11

376 clinical trials in Gothenburg, Sweden across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Gothenburg at a glance
376
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

376 trials in Gothenburg

Open in trial search

Prostate cancer metastatic

Recruiting

Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Astellas Pharma Global Development Inc.

Non-Hodgkin's lymphoma

Recruiting

Study on Lymphoblastic Lymphoma Treatment in Children and Adolescents Using Dexamethasone, Prednisone, and PEG-Asparaginase

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Cyclophosphamide
  • Sponsor:Universitaetsklinikum Muenster AöR

Prostate cancer

Recruiting

Study on the Safety and Effectiveness of 64Cu-DOTA-AE105 PET Imaging for Patients with Localized, Untreated Prostate Cancer

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:64Cu-Dota-Ae105
  • Sponsor:Curasight A/S

Factor VIII deficiency

Recruiting

Continued Access Study for Patients with Severe Hemophilia A Using Efanesoctocog Alfa

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Haematological malignancy+1

Recruiting

Study on the Safety and Effectiveness of Zilovertamab Vedotin for Children and Young Adults with Blood Cancers or Solid Tumors

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Zilovertamab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm malignant

Recruiting

Study on BI-1808 and Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bi-1808
  • Sponsor:BioInvent International AB

Metastases to liver+1

Recruiting

Study on Melphalan, Ipilimumab, and Nivolumab for Patients with Uveal Melanoma Liver Metastases

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Vaestra Goetalandsregionen

Plasma cell myeloma

Recruiting

Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel or Stem Cell Transplant for Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Relapsing multiple sclerosis+2

Recruiting

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Teriflunomide
  • Sponsor:Sanofi-Aventis Recherche & Developpement

VEXAS syndrome

Recruiting

Study of Azacitidine Treatment in Patients with VEXAS Syndrome

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Region Hovedstaden

Cardiac function disturbance postoperative

Recruiting

Study on Fibrinogen Concentrate (FGTW) for Managing Bleeding in Patients Undergoing Complex Cardiac Surgery

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Human Fibrinogen
  • Sponsor:LFB-Biotechnologies

Non-small cell lung cancer+1

Recruiting

Study on the Safety and Effects of Divarasib with Pembrolizumab and a Drug Combination for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Sweden

The busiest research cities in the country

All 65 cities in Sweden

Clinical research in Gothenburg

What the registry says about research in the country

01 Oncology Research

Multiple clinical trials focusing on innovative treatments for various types of leukemia, including chronic lymphocytic leukemia and acute myeloid leukemia. Studies are evaluating new therapeutic combinations and treatment approaches for lymphoma and pediatric cancers.

  • Chronic Myeloid Leukemia Treatment
  • Pediatric Cancer Immunotherapy
  • Follicular Lymphoma Management

Advanced research into targeted therapies and personalized treatment protocols for better patient outcomes.

02 Rare Diseases

Groundbreaking studies on rare genetic conditions including Niemann-Pick disease and gangliosidoses. Research focuses on evaluating novel treatments and investigating long-term outcomes for mucopolysaccharidosis and other rare disorders.

  • Genetic Disorder Treatments
  • Enzyme Replacement Therapies
  • Rare Disease Management

Innovative approaches to addressing complex rare diseases with targeted therapeutic interventions.

03 Cardiovascular and Renal Studies

Comprehensive research into cardiovascular disease prevention and treatment, alongside studies on various kidney conditions. Trials evaluating new medications for stroke prevention in atrial fibrillation and treatments for glomerular diseases.

  • Stroke Prevention
  • Kidney Disease Therapies
  • Cardiovascular Risk Management

Focus on developing effective treatments for both common and rare cardiovascular and renal conditions.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.